• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

EHA 2024 Highlights: Overcoming Challenges with Bispecific Antibodies in RRMM

Opinion
Video

Dr. Mikhael outlines the significant hurdles in bispecific antibody therapy, as presented at the European Hematology Association's 2024 conference.

Video content above is prompted by the following question:

  1. Results from the phase 1/2 MonumenTAL-1 study and phase 1B MonumenTAL-2 study were also presented at EHA 2024. How do the results from these two trials contribute to the evolving role of talquetamab in multiple myeloma?
  2. What is the value of long-term follow-up data in multiple myeloma? How does this impact use of treatment regimens?
  3. What challenges must be considered and overcome with bispecific antibody-containing regimens in RRMM?
Related Videos
Related Content
Current practices for IV isatuximab administration takes over an hour | image credit: NAMPIX - stock.adobe.com

Rapid IV Isatuximab Could Shift Care Practices in MM

February 13th 2025
Article

Reducing intravenous (IV) isatuximab delivery from 75 minutes to 30 minutes could provide a wealth of benefits to patients with multiple myeloma (MM) and health care systems alike.

Read More

cell abnormalities, multiple myeloma | image credit: LASZLO - stock.adobe.com

Prolonged Survival in MM: Insights From the Largest Ongoing US Registry

February 7th 2025
Article

The Connect MM Registry is the longest-running and largest registry in the US, providing invaluable prognostic insights into various patient and disease characteristics.

Read More

Kirollos Hanna, PharmD

An Argument for Outpatient Bispecific Antibody Delivery: Dr Kirollos Hanna

January 25th 2025
Article

Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.

Read More

Robert Rifkin, MD | Image credit: Rocky Mountain Cancer Centers

Study of Prophylactic Tocilizumab May Soon Add Talquetamab Arm

January 22nd 2025
Article

Read More

Infection risk concept; floating bacterial particles | image credit: ChaoticMind - stock.adobe.com

High Infection Risk in MM: Insights From the Preimmunotherapy Era

January 21st 2025
Article

Infection risk remains a prominent clinical concern for patients with multiple myeloma (MM), even with the advent of modern, novel therapies.

Read More

MRD status cannot be detected with a microscope and is achieved through bone marrow analysis | image credit: Arthur Constantine - stock.adobe.com

MRD Negativity: A "Robust" Predictor of Survival Outcomes in MM

January 13th 2025
Article

This meta-analysis sheds more light on the beneficial impact of multiple melanoma (MM) treatments and the predictive value of minimal residual disease (MRD) status for patient prognoses.

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.